BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Qin C, Yang G, Yang J, Ren B, Wang H, Chen G, Zhao F, You L, Wang W, Zhao Y. Metabolism of pancreatic cancer: paving the way to better anticancer strategies. Mol Cancer 2020;19:50. [PMID: 32122374 DOI: 10.1186/s12943-020-01169-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 14.5] [Reference Citation Analysis]
Number Citing Articles
1 Chang Y, Chang PM, Li C, Chan M, Lee Y, Chen M, Hsiao M. Aldolase A and Phospholipase D1 Synergistically Resist Alkylating Agents and Radiation in Lung Cancer. Front Oncol 2022;11:811635. [DOI: 10.3389/fonc.2021.811635] [Reference Citation Analysis]
2 Kokkinos J, Jensen A, Sharbeen G, McCarroll JA, Goldstein D, Haghighi KS, Phillips PA. Does the Microenvironment Hold the Hidden Key for Functional Precision Medicine in Pancreatic Cancer? Cancers (Basel) 2021;13:2427. [PMID: 34067833 DOI: 10.3390/cancers13102427] [Reference Citation Analysis]
3 Wu Y, Zeng H, Yu Q, Huang H, Fervers B, Chen ZS, Lu L. A Circulating Exosome RNA Signature Is a Potential Diagnostic Marker for Pancreatic Cancer, a Systematic Study. Cancers (Basel) 2021;13:2565. [PMID: 34073722 DOI: 10.3390/cancers13112565] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Chen H, Zu F, Zeng T, Chen Z, Wei J, Liu P, Li Z, Zhou L, Wang H, Tan H, Tan X. Prognostic Value and Correlation With Tumor Immune Infiltration of a Novel Metabolism-Related Gene Signature in Pancreatic Cancer. Front Oncol 2022;11:757791. [DOI: 10.3389/fonc.2021.757791] [Reference Citation Analysis]
5 Suzuki T, Otsuka M, Seimiya T, Iwata T, Kishikawa T, Koike K. The biological role of metabolic reprogramming in pancreatic cancer. MedComm (2020) 2020;1:302-10. [PMID: 34766124 DOI: 10.1002/mco2.37] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Huo J, Wu L, Zang Y. Development and Validation of a Novel Metabolic-Related Signature Predicting Overall Survival for Pancreatic Cancer. Front Genet 2021;12:561254. [PMID: 34122496 DOI: 10.3389/fgene.2021.561254] [Reference Citation Analysis]
7 Hayasaka R, Tabata S, Hasebe M, Ikeda S, Ohnuma S, Mori M, Soga T, Tomita M, Hirayama A. Metabolomic Analysis of Small Extracellular Vesicles Derived from Pancreatic Cancer Cells Cultured under Normoxia and Hypoxia. Metabolites 2021;11:215. [PMID: 33915936 DOI: 10.3390/metabo11040215] [Reference Citation Analysis]
8 Moldogazieva NT, Mokhosoev IM, Terentiev AA. Metabolic Heterogeneity of Cancer Cells: An Interplay between HIF-1, GLUTs, and AMPK. Cancers (Basel) 2020;12:E862. [PMID: 32252351 DOI: 10.3390/cancers12040862] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 14.0] [Reference Citation Analysis]
9 Parte S, Nimmakayala RK, Batra SK, Ponnusamy MP. Acinar to ductal cell trans-differentiation: A prelude to dysplasia and pancreatic ductal adenocarcinoma. Biochim Biophys Acta Rev Cancer 2021;1877:188669. [PMID: 34915061 DOI: 10.1016/j.bbcan.2021.188669] [Reference Citation Analysis]
10 Chang CK, Shih TT, Tien YW, Chang MC, Chang YT, Yang SH, Cheng MF, Chen BB. Metabolic Alterations in Pancreatic Cancer Detected by In Vivo 1H-MR Spectroscopy: Correlation with Normal Pancreas, PET Metabolic Activity, Clinical Stages, and Survival Outcome. Diagnostics (Basel) 2021;11:1541. [PMID: 34573881 DOI: 10.3390/diagnostics11091541] [Reference Citation Analysis]
11 Gu ZT, Li ZZ, Wang CF. Research advances of intracellular mechanisms underlying gemcitabine resistance in pancreatic cancer. Shijie Huaren Xiaohua Zazhi 2020; 28(22): 1150-1161 [DOI: 10.11569/wcjd.v28.i22.1150] [Reference Citation Analysis]
12 Fang K, Qu H, Wang J, Tang D, Yan C, Ma J, Gao L. Characterization of Modification Patterns, Biological Function, Clinical Implication, and Immune Microenvironment Association of m6A Regulators in Pancreatic Cancer. Front Genet 2021;12:702072. [PMID: 34603372 DOI: 10.3389/fgene.2021.702072] [Reference Citation Analysis]
13 Grapa CM, Mocan L, Crisan D, Florea M, Mocan T. Biomarkers in Pancreatic Cancer as Analytic Targets for Nanomediated Imaging and Therapy. Materials (Basel) 2021;14:3083. [PMID: 34199998 DOI: 10.3390/ma14113083] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Benedetti R, Benincasa G, Glass K, Chianese U, Vietri MT, Congi R, Altucci L, Napoli C. Effects of novel SGLT2 inhibitors on cancer incidence in hyperglycemic patients: a meta-analysis of randomized clinical trials. Pharmacol Res 2021;175:106039. [PMID: 34929299 DOI: 10.1016/j.phrs.2021.106039] [Reference Citation Analysis]
15 Huang WK, Chen Y, Su H, Chen TY, Gao J, Liu Y, Yeh CN, Li S. ARHGAP25 Inhibits Pancreatic Adenocarcinoma Growth by Suppressing Glycolysis via AKT/mTOR Pathway. Int J Biol Sci 2021;17:1808-20. [PMID: 33994864 DOI: 10.7150/ijbs.55919] [Reference Citation Analysis]
16 Novak I, Yu H, Magni L, Deshar G. Purinergic Signaling in Pancreas-From Physiology to Therapeutic Strategies in Pancreatic Cancer. Int J Mol Sci 2020;21:E8781. [PMID: 33233631 DOI: 10.3390/ijms21228781] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
17 Phyo JB, Woo A, Yu HJ, Lim K, Cho BH, Jung HS, Lee MY. Label-Free SERS Analysis of Urine Using a 3D-Stacked AgNW-Glass Fiber Filter Sensor for the Diagnosis of Pancreatic Cancer and Prostate Cancer. Anal Chem 2021;93:3778-85. [PMID: 33576598 DOI: 10.1021/acs.analchem.0c04200] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
18 Yu S, Zhang C, Xie KP. Therapeutic resistance of pancreatic cancer: Roadmap to its reversal. Biochim Biophys Acta Rev Cancer 2021;1875:188461. [PMID: 33157162 DOI: 10.1016/j.bbcan.2020.188461] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
19 Chen X, Zeh HJ, Kang R, Kroemer G, Tang D. Cell death in pancreatic cancer: from pathogenesis to therapy. Nat Rev Gastroenterol Hepatol 2021. [PMID: 34331036 DOI: 10.1038/s41575-021-00486-6] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
20 Rai V, Agrawal S. Targets (Metabolic Mediators) of Therapeutic Importance in Pancreatic Ductal Adenocarcinoma. Int J Mol Sci 2020;21:E8502. [PMID: 33198082 DOI: 10.3390/ijms21228502] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Gu Z, Du Y, Zhao X, Wang C. Tumor microenvironment and metabolic remodeling in gemcitabine-based chemoresistance of pancreatic cancer. Cancer Lett 2021;521:98-108. [PMID: 34461181 DOI: 10.1016/j.canlet.2021.08.029] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Abdel Hadi N, Reyes-Castellanos G, Carrier A. Targeting Redox Metabolism in Pancreatic Cancer. Int J Mol Sci 2021;22:1534. [PMID: 33546421 DOI: 10.3390/ijms22041534] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
23 Qiu H, Wang D, Miao H. Analysis of the Effect of Robots in the Treatment of Pancreatic Cancer Based on Smart Medicine. J Healthc Eng 2021;2021:9734882. [PMID: 34589193 DOI: 10.1155/2021/9734882] [Reference Citation Analysis]
24 Reyes-Castellanos G, Masoud R, Carrier A. Mitochondrial Metabolism in PDAC: From Better Knowledge to New Targeting Strategies. Biomedicines 2020;8:E270. [PMID: 32756381 DOI: 10.3390/biomedicines8080270] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
25 Chen C, Wu H, Kong D, Xu Y, Zhang Z, Chen F, Zou L, Li Z, Shui J, Luo H, Liu SH, Yu J, Wang K, Brunicardi FC. Transcriptome sequencing analysis reveals unique and shared antitumor effects of three statins in pancreatic cancer. Oncol Rep 2020;44:2569-80. [PMID: 33125137 DOI: 10.3892/or.2020.7810] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Bulle A, Dekervel J, Deschuttere L, Nittner D, Van Cutsem E, Verslype C, van Pelt J. Anti-Cancer Activity of Acriflavine as Metabolic Inhibitor of OXPHOS in Pancreas Cancer Xenografts. Onco Targets Ther 2020;13:6907-16. [PMID: 32764982 DOI: 10.2147/OTT.S245134] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Tang S, Hang Y, Ding L, Tang W, Yu A, Zhang C, Sil D, Xie Y, Oupický D. Intraperitoneal siRNA Nanoparticles for Augmentation of Gemcitabine Efficacy in the Treatment of Pancreatic Cancer. Mol Pharm 2021;18:4448-58. [PMID: 34699242 DOI: 10.1021/acs.molpharmaceut.1c00653] [Reference Citation Analysis]
28 Chiu CF, Hsu MI, Yeh HY, Park JM, Shen YS, Tung TH, Huang JJ, Wu HT, Huang SY. Eicosapentaenoic Acid Inhibits KRAS Mutant Pancreatic Cancer Cell Growth by Suppressing Hepassocin Expression and STAT3 Phosphorylation. Biomolecules 2021;11:370. [PMID: 33801246 DOI: 10.3390/biom11030370] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
29 Zhu PF, Wang MX, Chen ZL, Yang L. Targeting the Tumor Microenvironment: A Literature Review of the Novel Anti-Tumor Mechanism of Statins. Front Oncol 2021;11:761107. [PMID: 34858839 DOI: 10.3389/fonc.2021.761107] [Reference Citation Analysis]
30 Wang F, Huang L, Zhang J, Fan J, Wu H, Xu J. Dyslipidemia in Chinese Pancreatic Cancer Patients: A Two-Center Retrospective Study. J Cancer 2021;12:5338-44. [PMID: 34335950 DOI: 10.7150/jca.60340] [Reference Citation Analysis]
31 Pretta A, Lai E, Persano M, Donisi C, Pinna G, Cimbro E, Parrino A, Spanu D, Mariani S, Liscia N, Dubois M, Migliari M, Impera V, Saba G, Pusceddu V, Puzzoni M, Ziranu P, Scartozzi M. Uncovering key targets of success for immunotherapy in pancreatic cancer. Expert Opin Ther Targets 2021;:1-19. [PMID: 34806517 DOI: 10.1080/14728222.2021.2010044] [Reference Citation Analysis]
32 Amrutkar M, Gladhaug IP. Stellate Cells Aid Growth-Permissive Metabolic Reprogramming and Promote Gemcitabine Chemoresistance in Pancreatic Cancer. Cancers (Basel) 2021;13:601. [PMID: 33546284 DOI: 10.3390/cancers13040601] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Han X, Zhang WH, Wang WQ, Yu XJ, Liu L. Cancer-associated fibroblasts in therapeutic resistance of pancreatic cancer: Present situation, predicaments, and perspectives. Biochim Biophys Acta Rev Cancer 2020;1874:188444. [PMID: 33031899 DOI: 10.1016/j.bbcan.2020.188444] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
34 Yu Y, Sun X, Chen F, Liu M. Genetic Alteration, Prognostic and Immunological Role of Acyl-CoA Synthetase Long-Chain Family Member 4 in a Pan-Cancer Analysis. Front Genet 2022;13:812674. [DOI: 10.3389/fgene.2022.812674] [Reference Citation Analysis]
35 Shindo H, Harada-Shoji N, Ebata A, Sato M, Soga T, Miyashita M, Tada H, Kawai M, Kosaka S, Onuki K, Usami S, Furumoto S, Hayashi S, Abe T, Suzuki T, Ishida T, Sasano H. Targeting Amino Acid Metabolic Reprogramming via L-Type Amino Acid Transporter 1 (LAT1) for Endocrine-Resistant Breast Cancer. Cancers (Basel) 2021;13:4375. [PMID: 34503187 DOI: 10.3390/cancers13174375] [Reference Citation Analysis]
36 Roth HE, Bhinderwala F, Franco R, Zhou Y, Powers R. DNAJA1 Dysregulates Metabolism Promoting an Antiapoptotic Phenotype in Pancreatic Ductal Adenocarcinoma. J Proteome Res 2021;20:3925-39. [PMID: 34264680 DOI: 10.1021/acs.jproteome.1c00233] [Reference Citation Analysis]
37 Espiau-Romera P, Courtois S, Parejo-Alonso B, Sancho P. Molecular and Metabolic Subtypes Correspondence for Pancreatic Ductal Adenocarcinoma Classification.J Clin Med. 2020;9. [PMID: 33371431 DOI: 10.3390/jcm9124128] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
38 Chen Q, Pu N, Yin H, Zhang J, Zhao G, Lou W, Wu W. A metabolism-relevant signature as a predictor for prognosis and therapeutic response in pancreatic cancer. Exp Biol Med (Maywood) 2021;:15353702211049220. [PMID: 34632851 DOI: 10.1177/15353702211049220] [Reference Citation Analysis]
39 Andersen HB, Ialchina R, Pedersen SF, Czaplinska D. Metabolic reprogramming by driver mutation-tumor microenvironment interplay in pancreatic cancer: new therapeutic targets. Cancer Metastasis Rev 2021. [PMID: 34855109 DOI: 10.1007/s10555-021-10004-4] [Reference Citation Analysis]
40 Gu ZT, Li ZZ, Wang CF. Advances in research of extracellular mechanisms underlying gemcitabine resistance in pancreatic cancer. Shijie Huaren Xiaohua Zazhi 2021; 29(8): 421-434 [DOI: 10.11569/wcjd.v29.i8.421] [Reference Citation Analysis]
41 Rizzo AM, Colombo I, Montorfano G, Zava S, Corsetto PA. Exogenous Fatty Acids Modulate ER Lipid Composition and Metabolism in Breast Cancer Cells. Cells 2021;10:175. [PMID: 33467111 DOI: 10.3390/cells10010175] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
42 Nollmann FI, Ruess DA. Targeting Mutant KRAS in Pancreatic Cancer: Futile or Promising? Biomedicines 2020;8:E281. [PMID: 32796566 DOI: 10.3390/biomedicines8080281] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]